Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial.

ABSTRACT:

Purpose

To report the results of the Single Fraction Early Prostate Irradiation (SiFEPI) phase 2 prospective trial.

Materials/methods

The SiFEPI trial (NCT02104362) evaluated a single fraction of high-dose rate brachytherapy (HDB) for low- (LR) and favorable-intermediate (FIR) risk prostate cancers. After rectal spacer placement, a single fraction of 20 Gy was delivered to the prostate. Oncological outcome (biochemical (bRFS) and local (lRFS) relapses, disease-free (DFS) and overall (OS) survivals and toxicity (acute/late genito-urinary (GU), gastro-intestinal (GI) and sexual (S) toxicities were investigated.

Results

From 03/2014 to 10/2017, 35 pts were enrolled, of whom 33 were evaluable. With a median age of 66 y [46-79], 25 (76 %) and 8 (24 %) pts were LR an

SUBMITTER: Hannoun-Levi JM 

PROVIDER: S-EPMC9449500 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature